Our sell-side clients include entrepreneurial founders approaching a liquidity event, family office business owners rationalising their holdings, and corporate boards divesting non-core business units. In each case, the objective is the same: maximise corporate valuation while safeguarding the enterprise, its people, and its strategic intent throughout the process.
Superior outcomes are engineered, not hoped for. We construct controlled, confidential processes that place pre-screened strategic acquirers and financial sponsors in genuine competition ??? anonymised outreach, disciplined information staging, and precisely sequenced management interactions that preserve leverage until terms are secured.
Divestiture processes expose sensitive commercial information. Our controlled transaction architecture ??? staged disclosures, watermarked collateral, and tightly managed virtual data rooms ??? protects client IP, operational data, and strategic intent at every phase of the engagement.
Advising an integrated healthcare technology and pharmaceutical commerce platform on institutional fundraising to support business expansion and technology scaling.
Advising a pharmaceutical manufacturing company on strategic capital raising to expand manufacturing capacity and strengthen market position.
Advising an export-oriented pharmaceutical formulations manufacturer on strategic financial advisory and transaction-readiness initiatives.
